Anguidine: a broad phase II study of the Southeastern Cancer Study Group.
Anguidine, a phase II agent, was used to treat 276 patients with solid tumors. The overall evaluability rate was 68%. Hematologic toxicity was substantial but not prohibitive. There were no complete responses, two partial responses, and 12 stabilizations.
D000230:Adenocarcinoma / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D010976:Platelet Count; D012717:Sesquiterpenes / Q000627:therapeutic use*; D014255:Trichothecenes / Q000009:adverse effects / Q000627:therapeutic use*
D012717:Sesquiterpenes; D014255:Trichothecenes; C001809:diacetoxyscirpenol